Synthesis And Preclinical Evaluation Of The Lu-177-Dota-Psma(Inhibitor)-Lys(3)-Bombesin Heterodimer Designed As A Radiotheranostic Probe For Prostate Cancer
NUCLEAR MEDICINE COMMUNICATIONS（2019）
摘要
Supplemental Digital Content is available in the text.
更多查看译文
关键词
heterobivalent radiopharmaceutical, heterodimer radiotracer, lutetium-177, Lys(3)-bombesin, prostate-specific membrane antigen inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要